What We Know (and Don't Know) About the Endocannabinoid System and PTSD Treatment | Research

The takeaway

A review found that animal studies consistently show endocannabinoid modulation can improve PTSD-related behaviors and fear memory, but human research remains mixed and insufficient to support cannabinoid therapy for PTSD.

PTSD researchers, psychiatrists considering cannabinoid therapies, veterans' health advocates.

Animal studies consistently support endocannabinoid modulation for PTSD; human data remains mixed

What the researchers found

Preclinical literature is reasonably consistent in showing that endocannabinoid system modulation can affect fear memory processes relevant to PTSD. However, emerging human literature is mixed and inconsistent. The review identifies several potential reasons for the human-animal discrepancy and calls for clinical trials and carefully designed human experimental studies.

Why it matters

PTSD is often treatment-resistant, affecting an estimated 6% of the US population. Cannabinoid therapy has been proposed as a potential alternative, but this review highlights the gap between promising animal data and inconsistent human evidence, cautioning against premature clinical adoption.

The numbers in context

Review covers preclinical and clinical literature on endocannabinoid modulation in PTSD; notes that PTSD is often treatment-resistant; calls for clinical trials before cannabinoid therapy can be considered a treatment approach.

How the study worked

Narrative review synthesizing animal and human research on endocannabinoid modulation effects on posttraumatic symptoms, behaviors, and relevant memory processes, with analysis of why human findings have been inconsistent.

What this study cannot tell us

Narrative review methodology is less systematic than systematic review. The field is rapidly evolving, so conclusions may not reflect the very latest studies. Does not provide a meta-analytic estimate of effect sizes across studies.

How to read the evidence

Moderate: Comprehensive review covering both animal and human literature with thoughtful analysis of discrepancies, though narrative methodology limits systematic rigor.

When this study was published

Published in 2025, reflecting current state of research.

The bigger picture

The endocannabinoid system's role in fear extinction and emotional memory makes it a biologically plausible target for PTSD treatment. This review serves as a reality check, acknowledging the promise while emphasizing that human evidence has not yet caught up to animal data.

Questions still open

Why are human studies of cannabinoids for PTSD yielding inconsistent results? What logistical challenges of cannabinoid administration need to be resolved before clinical trials can succeed? Which specific endocannabinoid targets are most promising for PTSD?

Common questions

Can cannabis treat PTSD?

The review concludes that while animal studies are promising, human evidence is too mixed and inconsistent to support cannabinoid therapy for PTSD at this time. The authors call for properly designed clinical trials before any recommendations can be made.

Why might animal results not translate to humans?

The review explores several reasons: differences in how fear memory is studied in animals versus humans, variability in cannabinoid doses and formulations used in human studies, individual differences in endocannabinoid system function, and the complexity of human PTSD compared to animal fear conditioning models.

Read the original research

Understanding the Role of Endocannabinoids in Posttraumatic Stress Disorder.

International journal of molecular sciences, 26(12)

View on PubMed ↗Publisher’s paper ↗

Citation

Ney, Luke. (2025). Understanding the Role of Endocannabinoids in Posttraumatic Stress Disorder.. International journal of molecular sciences, 26(12). https://doi.org/10.3390/ijms26125527